Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

NCT06495541 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT06495541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06495541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
April 1, 2026
Completion date
July 30, 2028
Enrollment
500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, pyrotinib, rws